NCT04355117View on ClinicalTrials.gov

A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Migraine
Interventions
DRUG

Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.

Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.

Trial Locations (1)

Unknown

Sendai Zutsu No-Shinkei Clinic, Sendai

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY